RANVET'S PERGOLIDE

国家: 澳大利亚

语言: 英文

来源: APVMA (Australian Pesticides and Veterinary Medicines Authority)

现在购买

资料单张 资料单张 (PIL)
20-06-2017

有效成分:

PERGOLIDE MESYLATE

可用日期:

RANVET PTY. LIMITED

INN(国际名称):

pergolide mesylate(1mg/5mL)

药物剂型:

ORAL SOLUTION/SUSPENSION

组成:

PERGOLIDE MESYLATE AMINO Active 1.0 mg/5ml

每包单位数:

200mL

类:

VM - Veterinary Medicine

治疗组:

HORSE | PONY | COLT | DONKEY | ENDURANCE HORSE | FILLY | FOAL | GELDING | HIGH PERFORMANCE HORSES | HORSES AT STUD | MARE | PACE

治疗领域:

ENDOCRINE SYSTEM

疗效迹象:

CUSHINGS DISEASE | HYPERADRENOCORTISISM | PITUITARY DEPENDENT HYPERDRENO

產品總結:

Poison schedule: 4; Withholding period: MEAT WHP (HORSES): NOT TO BE USED in h orse intended for human consumption.; Host/pest details: HORSE: [CUSHINGS DISEASE]; PONY: [CUSHINGS DISEASE]; Poison schedule: 4; Withholding period: ; Host/pest details: HORSE: [CUSHINGS DISEASE]; PONY: [CUSHINGS DISEASE]; Aids in the therapy of equine Cushing's syndrome.This product is contraindicated in horses hypersensitive to it or other ergot derivatives. Use with caution in pregnant or lactating mares as safe use in these groups has not been established.

授权状态:

Registered

授权日期:

2022-07-01

资料单张

                                R
T PT
LTD
ANVE
ty
Ranvet's Pergolide -
Main Panel
Date:
September
13,
2010
Version:
3
Page 1
of
1
CIN
:
000
Carton Label
Anything
above
this
line
is
not
draft
/
text
label.
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
RANVET'S PERGOLIDE
Active
Constituent:
Pergalide mesylate 1mg/5mL
Aids in the therapy of equine Cushing's syndrome
200
mL RLP APPROVED
Info
PEST

Verified
RANVET PTY LTD
Ranvet's
Pergolide
-
Ancillary
Panels
Date:
September
13,
2010
Version:
3
Page 2
of
1
CIN
:
000
Carton Label
Anything
above
this
line is
not
draft
/
text
label.
INDICATlONS
Pergolide mesylate is a potent dopamine agonist
for the control
of clinical
signs
associated with equine Cushing's syndrome in horses and ponies.
These signs
may include lethargy ; long, poor-quality hair coat that
fails to shed; weight
loss;
pot-bellied appearance ; dry scaly skin;
skin infections;
polyuria (increased
frequency of urination) and polydipsia (increased drinking) ; chronic
laminitis and
colic .
DIRECTIONS FOR USE
Contraindications:
This product
is contraindicated in horses hypersensitive to it or other ergot
derivatives.
Precautions:
Use with caution in pregnant
or lactating mares as safe use in these groups has not
been established.
Dosage and
administration:
Administer orally over the tongue once daily. A syringe should be used
for accurate
dose measurement.
An initial
starting dose of 0.002mg/kg
(1
mg/500kg bodyweight)
daily is
recommended.
Each 5mLdose provides 1mg pergolide mesylate.
The dose may be
gradually increased if clinical
improvement fails to occur after one to two months of
therapy.
Consult
your veterinarian before altering the recommended dose.
If the
dose is to be increased it is recommended that
0.5mg increments be assessed
before higher daily doses are employed.
A favourable clinical
response to therapy will
be associated with improvement or
normalisation of results in the dexamethasone suppression and plasma
ACTH tests
and an improvement in clinical
signs .
Treatment will
be required for t
                                
                                阅读完整的文件